ATE369330T1 - O-desmethyl-venlafaxine succinat salz - Google Patents

O-desmethyl-venlafaxine succinat salz

Info

Publication number
ATE369330T1
ATE369330T1 AT02718949T AT02718949T ATE369330T1 AT E369330 T1 ATE369330 T1 AT E369330T1 AT 02718949 T AT02718949 T AT 02718949T AT 02718949 T AT02718949 T AT 02718949T AT E369330 T1 ATE369330 T1 AT E369330T1
Authority
AT
Austria
Prior art keywords
desmethyl
succinate salt
venlafaxine succinate
venlafaxine
salt
Prior art date
Application number
AT02718949T
Other languages
English (en)
Inventor
Anthony Hadfield
Syed Shah
Michael Winkley
Karen Sutherland
James Provost
Aeri Park
Rex Shipplett
Brenton Russell
Beat Weber
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26952945&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE369330(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of ATE369330T1 publication Critical patent/ATE369330T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/64—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT02718949T 2001-02-12 2002-02-11 O-desmethyl-venlafaxine succinat salz ATE369330T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26821401P 2001-02-12 2001-02-12
US29796301P 2001-06-13 2001-06-13

Publications (1)

Publication Number Publication Date
ATE369330T1 true ATE369330T1 (de) 2007-08-15

Family

ID=26952945

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02718949T ATE369330T1 (de) 2001-02-12 2002-02-11 O-desmethyl-venlafaxine succinat salz

Country Status (30)

Country Link
US (5) US6673838B2 (de)
EP (3) EP1864967A1 (de)
JP (1) JP4220243B2 (de)
KR (1) KR100875610B1 (de)
CN (2) CN101671260A (de)
AR (2) AR032671A1 (de)
AT (1) ATE369330T1 (de)
AU (1) AU2002250058B2 (de)
BR (1) BR0207157A (de)
CA (2) CA2666611A1 (de)
CY (1) CY1106952T1 (de)
DE (1) DE60221642T3 (de)
DK (1) DK1360169T3 (de)
EA (1) EA011451B1 (de)
ES (1) ES2290281T5 (de)
HN (1) HN2002000030A (de)
HU (1) HUP0303128A3 (de)
IL (4) IL157340A0 (de)
MX (1) MXPA03007043A (de)
NO (1) NO328807B1 (de)
NZ (1) NZ539791A (de)
PA (1) PA8539901A1 (de)
PE (1) PE20020877A1 (de)
PL (2) PL211788B1 (de)
PT (1) PT1360169E (de)
SI (1) SI1360169T1 (de)
TW (1) TWI318201B (de)
UY (1) UY27175A1 (de)
WO (1) WO2002064543A2 (de)
ZA (1) ZA200307116B (de)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9914826A (pt) 1998-10-30 2001-11-06 Ajinomoto Kk Processo de cristalização de cristais de éster metìlico de n- [n-(3,3-dimetilbutil)-l-alfa-aspartil] -l-fenilalanina
US6342533B1 (en) 1998-12-01 2002-01-29 Sepracor, Inc. Derivatives of (−)-venlafaxine and methods of preparing and using the same
PL350924A1 (en) * 1999-04-06 2003-02-10 Sepracor Inc Derivatives of venlafaxine and methods of preparing and using the same
DE60221642T3 (de) * 2001-02-12 2017-10-26 Wyeth LLC (n.d.Ges.d. Staates Delaware) O-desmethyl-venlafaxine succinat salz
US20050244498A1 (en) * 2001-09-14 2005-11-03 Biovail Laboratories, Inc. Modified-release compositions of at least one form of venlafaxine
UA80543C2 (en) 2001-12-04 2007-10-10 Wyeth Corp Method for the preparation of o-desmethylvenlafaxine
AR039162A1 (es) * 2002-03-28 2005-02-09 Synthon Bv Formulaciones de venlafaxina de liberacion extendida
BR0311693A (pt) * 2002-06-10 2005-03-22 Wyeth Corp Sal de formato de o-desmetil-venlafaxina
EP1539172A1 (de) * 2002-08-29 2005-06-15 Arachnova Therapeutics Ltd. Neue therapeutische anwendungen von (4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl) thieno[2,3-d]pyrimidin
US7345096B2 (en) 2002-10-15 2008-03-18 Wyeth Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
CA2523083C (en) 2003-04-25 2014-07-08 Gilead Sciences, Inc. Antiviral phosphonate analogs
JP2004359665A (ja) * 2003-05-30 2004-12-24 Rohm & Haas Co 生体利用性増強剤を含有する治療組成物
US7491723B2 (en) 2003-10-14 2009-02-17 Wyeth Alkanol and cycloalkanol-amine derivatives and methods of their use
US7402698B2 (en) 2003-10-14 2008-07-22 Wyeth Secondary amino-and cycloamino-cycloalkanol derivatives and methods of their use
US7524846B2 (en) 2003-10-14 2009-04-28 Wyeth Arylalkyl- and cycloalkylalkyl-piperazine derivatives and methods of their use
US7419980B2 (en) 2003-10-14 2008-09-02 Wyeth Fused-aryl and heteroaryl derivatives and methods of their use
US7531543B2 (en) 2003-10-14 2009-05-12 Wyeth Phenylpiperazine cycloalkanol derivatives and methods of their use
US7365076B2 (en) 2003-10-14 2008-04-29 Wyeth Substituted aryl cycloalkanol derivatives and methods of their use
US7550485B2 (en) 2003-10-14 2009-06-23 Wyeth Substituted N-heterocycle derivatives and methods of their use
WO2005077340A1 (en) 2004-02-06 2005-08-25 Wyeth Multiparticulate o-desmethylvenlafaxine salts and uses thereof
US7414052B2 (en) 2004-03-30 2008-08-19 Wyeth Phenylaminopropanol derivatives and methods of their use
US7517899B2 (en) 2004-03-30 2009-04-14 Wyeth Phenylaminopropanol derivatives and methods of their use
US7439280B2 (en) * 2004-04-06 2008-10-21 Basf Corporation Lignocellulosic composite material and method for preparing the same
CA2574310A1 (en) * 2004-07-22 2006-02-02 Wyeth Method for treating nervous system disorders and conditions
BRPI0512182A (pt) * 2004-07-22 2008-02-19 Wyeth Corp método para o tratamento de condições e desordens do sistema nervoso
WO2006012476A2 (en) * 2004-07-22 2006-02-02 Wyeth Method for treating nervous system disorders and conditions
PL216369B1 (pl) 2004-07-27 2014-03-31 Gilead Sciences Pochodne fosfonianowe, kompozycje farmaceutyczne zawierające te pochodne oraz zastosowanie tych pochodnych do wytwarzania leku do hamowania wirusa HIV
US20060193912A1 (en) * 2005-02-28 2006-08-31 Penwest Pharmaceuticals Co. Controlled release O-desmethylvenlafaxine formulations
CN101151026A (zh) * 2005-03-31 2008-03-26 惠氏公司 O-去甲文拉法辛和巴泽昔芬联合产品及其应用
CN1955159B (zh) 2005-06-17 2010-11-24 山东绿叶制药有限公司 用于阻断5-羟色胺以及去甲基肾上腺素再摄取的化合物,其制备方法及其用途
JP2009500420A (ja) * 2005-07-06 2009-01-08 セプラコア インコーポレーテッド エスゾピクロン及びｏ−デスメチルベンラファキシンの組み合わせ、並びに閉経期並びに気分、不安、及び認知障害の治療方法
US7687520B2 (en) 2005-07-15 2010-03-30 Wyeth Llc Serotonin and norepinephrine reuptake inhibitors and uses thereof
US7595340B2 (en) 2005-07-15 2009-09-29 Wyeth Serotonin and norepinephrine reuptake inhibitor and uses thereof
AR057662A1 (es) * 2005-07-15 2007-12-12 Wyeth Corp Inhibidor de la recaptacion doble de serotonina y norepinefrina con alta selectividad y uso del mismo
EP1904059A2 (de) * 2005-07-21 2008-04-02 Wyeth a Corporation of the State of Delaware Verfahren zur behandlung von erkrankungen und zuständen des nervensystems
GT200600397A (es) * 2005-09-07 2007-08-28 Formulas topicas conteniendo o-desmetil venlafaxina (odv) o sus sales
GT200600396A (es) * 2005-09-07 2007-04-23 Dispositivos para la aplicacion de medicamentos transdermicos conteniendo o-desmetil venlafaxina (odv) o sus sales
CN1332946C (zh) * 2005-10-21 2007-08-22 中国人民解放军军事医学科学院放射与辐射医学研究所 作用于中枢神经系统的前药
WO2007064697A1 (en) * 2005-12-01 2007-06-07 Auspex Pharmaceuticals, Inc. Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity
WO2007067501A1 (en) * 2005-12-05 2007-06-14 Wyeth Process for selective synthesis of enantiomers of substituted 1-(2-amino-1-phenyl-ethyl)-cyclohexanols
EP1973866A1 (de) 2005-12-20 2008-10-01 Synthon B.V. Verfahren zur herstellung von desvenlafaxin
JP2008546718A (ja) 2006-04-17 2008-12-25 テバ ファーマシューティカル インダストリーズ リミティド 実質的に純粋なｏ−デスメチルベンラファキシン及びその調製方法。
MX2007016179A (es) 2006-04-17 2008-03-11 Teva Pharma Formas cristalinas de o-desmetilvenlafaxina.
DK2020996T3 (da) * 2006-05-16 2012-02-27 Gilead Sciences Inc Fremgangsmåder og sammensætninger til behandling af hæmatologiske sygdomme
US20090137846A1 (en) * 2006-07-26 2009-05-28 Valerie Niddam-Hildesheim Processes for the synthesis of O-Desmethylvenlafaxine
EP1934167A2 (de) * 2006-07-26 2008-06-25 Teva Pharmaceutical Industries Ltd. Verfahren zur synthese von o-desmethylvenlafaxin
US20090069601A1 (en) * 2006-07-26 2009-03-12 Valerie Niddam-Hildesheim Processes for the synthesis of O-desmethylvenlafaxine
WO2008013993A2 (en) * 2006-07-26 2008-01-31 Teva Pharmaceutical Industries Ltd. Processes for the synthesis of o-desmethylvenlafaxine
US20080221356A1 (en) * 2006-07-26 2008-09-11 Valerie Niddam-Hildesheim Processes for the synthesis of O-desmethylvenlafaxine
WO2008015584A2 (en) * 2006-08-04 2008-02-07 Medichem, S.A. Improved process for synthesizing desvenlafaxine free base and salts or solvates thereof
US20100035994A1 (en) * 2006-08-08 2010-02-11 Gore Vinayak G Novel hydrate form of o-desmethyl venlafaxine succinate
AU2007311625A1 (en) * 2006-10-18 2008-04-24 Generics [Uk] Limited Polymorphs of O-desmethyl venlafaxine succinate
PE20081138A1 (es) * 2006-10-25 2008-09-18 Wyeth Corp Metabolitos aislados de hidroxi y n-oxido y derivados de desmetil venlafaxina y metodos de tratamiento
PT2125786E (pt) * 2006-12-21 2011-04-21 Pfizer Prod Inc Sal succinato de 2-((4-(1-metil-4-(piridin-4-il)-1hpirazol- 3-il)fenoxi)metil)quinolina
WO2009027766A2 (en) * 2006-12-22 2009-03-05 Medichem, S.A. New crystalline solid forms of o-desvenlafaxine base
US7820716B2 (en) * 2007-01-08 2010-10-26 Mai De Ltd Crystalline polymorphs of desvenlafaxine succinate and their preparations
AR064987A1 (es) * 2007-01-22 2009-05-06 Medichem Sa Proceso mejorado para sintetizar desvenlafaxina como base libre y sales o solvatos de la misma
AU2008211711A1 (en) * 2007-01-31 2008-08-07 Generics [Uk] Limited Process for the preparation of O-desmethyl venlafaxine
SG175611A1 (en) * 2007-02-21 2011-11-28 Sepracor Inc Solid forms comprising (-) o-desmethylvenlafaxine and uses thereof
WO2008110338A1 (en) * 2007-03-09 2008-09-18 Synthon B.V. Polymorph of desvenlafaxine succinate
EP2049465A2 (de) * 2007-03-14 2009-04-22 Teva Pharmaceutical Industries Ltd. Verfahren zur herstellung von o-desmethylvenlafaxin in festem zustand
AU2008251773A1 (en) 2007-03-15 2008-11-20 Auspex Pharmaceuticals, Inc. Deuterated venlafaxines and 0-desmetylvenlafaxines with serotoninergic and / or norepinephrinergic activity
US20090012182A1 (en) * 2007-06-15 2009-01-08 Alexandr Jegorov Crystal forms of O-desmethylvenlafaxine succinate
CA2692738A1 (en) * 2007-07-12 2009-01-15 Dr. Reddy's Laboratories, Ltd. O-desmethylvenlafaxine
US8329952B2 (en) * 2007-07-16 2012-12-11 Matrix Laboratories Limited Process for the preparation of O-desmethylvenlafaxine succinate polymorphic forms
WO2009017813A1 (en) * 2007-08-02 2009-02-05 Teva Pharmaceutical Industries Ltd. O-desmethyl venlafaxine saccharinate
US20090076162A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched desvenlafaxine
CA2702664A1 (en) * 2007-10-16 2009-04-23 Alphapharm Pty Ltd Controlled-release pharmaceutical formulation
EP2212275A2 (de) * 2007-10-22 2010-08-04 Actavis Group PTC EHF Feste formen von (±)-o-desmethylvenlafaxin-salzen
CA2703647A1 (en) 2007-10-26 2009-04-30 Generics [Uk] Limited Process for preparing o-desmethylvenlafaxine
KR101343027B1 (ko) * 2007-11-26 2013-12-18 테바 파마슈티컬 인더스트리즈 리미티드 Ｏ-데스메틸벤라팍신 푸마레이트의 결정형
EP2085377A1 (de) * 2008-01-29 2009-08-05 LEK Pharmaceuticals D.D. Neuartige Salze von O-Desmethyl-Venlafaxin
EP2262758A4 (de) * 2008-03-12 2011-12-07 Reddys Lab Ltd Dr O-desmethylvenlafaxin-salze
WO2009118758A2 (en) * 2008-03-24 2009-10-01 Sun Pharmaceutical Industries Ltd. Novel crystalline forms of desvenlafaxine succinate
IN2008CH00818A (de) * 2008-04-01 2009-10-09 Actavis Group Ptc Ehf
KR100965527B1 (ko) * 2008-05-08 2010-06-23 제일약품주식회사 신규(4-(2-(디메틸아미노)-1-(1-하이드록시사이클로헥실)에틸)페녹시)포스페이트 또는 이의 약학적으로 허용가능한 염,이의 제조방법 및 이를 유효성분으로 함유하는 중추신경계질환 예방 및 치료용 조성물
EP2119696A1 (de) * 2008-05-16 2009-11-18 Krka Zubereitung von O-Desmethylvenlafaxin-Salzen
EP2119695A1 (de) * 2008-05-16 2009-11-18 Krka Zubereitung von O-Desmethylvenlafaxin-Salzen
KR20100132069A (ko) * 2008-06-16 2010-12-16 테바 파마슈티컬 인더스트리즈 리미티드 Ｏ-데스메틸벤라팍신염의 고체 상태
JP5620376B2 (ja) 2008-07-08 2014-11-05 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖ阻害剤化合物の塩
US20100016638A1 (en) * 2008-07-21 2010-01-21 Zdenko Hamersak Method for preparation of o-desmethylvenlafaxine using polythiolates
CN102164886A (zh) * 2008-07-30 2011-08-24 基因里克斯(英国)有限公司 用于制备o-去甲文拉法辛的方法
KR101041960B1 (ko) * 2008-08-14 2011-06-16 주식회사 루미맥스테크놀러지 파워 ｌｅｄ를 구비하는 램프 장치
EP2191822A1 (de) 2008-11-26 2010-06-02 LEK Pharmaceuticals d.d. Pharmazeutische Zusammensetzungen mit kontrollierter Freisetzung, die O-Desmethylvenlafaxin umfassen
CZ2008756A3 (cs) * 2008-11-27 2010-03-24 Zentiva, A. S. Zpusob prípravy desvenlafaxinu a jeho solí
ES2343050B1 (es) * 2008-12-16 2011-06-14 Chemo Iberica, S.A. Procedimiento para la preparacion de desvenlafaxina y sus sales de adicion de acido farmaceuticamente aceptables.
CZ200969A3 (cs) * 2009-02-06 2010-06-30 Zentiva, K.S. Nové soli desvenlafaxinu a zpusob jejich prípravy
CZ2009454A3 (cs) 2009-07-15 2010-11-10 Zentiva, K. S. Zpusob prípravy desvenlafaxinu a jeho solí
JP2012532923A (ja) 2009-07-16 2012-12-20 シプラ・リミテッド Ｏ−デスメチルベンラファキシンの製造方法及びそれに使用される中間体
US20110098506A1 (en) * 2009-10-26 2011-04-28 Intas Pharmaceuticals Limited Method of preparing o-desmethylvenlafaxine
US8754261B2 (en) 2009-12-16 2014-06-17 Pharmathen S.A. Process for the preparation of O-desmethyl-venlafaxine and salts thereof
US20110184067A1 (en) * 2010-01-25 2011-07-28 Intas Pharmaceuticals Ltd. O-desmethylvenlafaxine succinate polymorph & process for preparing thereof
WO2011121452A2 (en) * 2010-03-29 2011-10-06 Pliva Hrvatska D.O.O. Crystal forms of o-desmethylvenlafaxine fumarate
EP2552419A2 (de) 2010-03-31 2013-02-06 Wockhardt Limited Desvenlafaxin oder desvenlafaxin-salze enthaltende darreichungsform mit modifizierter freisetzung
CZ303249B6 (cs) 2010-04-06 2012-06-20 Zentiva, K.S. Zpusob výroby 4-(2-(substituovaných)-1-(1-hydroxycyklohexyl)ethyl)fenolu O-demethylací jejich methyletheru pomocí nepáchnoucích aromatických thiolu
CN102212014B (zh) * 2010-04-09 2013-12-25 江苏豪森医药集团有限公司 O-去甲基-文拉法辛的谷氨酸盐的晶型、其制备方法及其在医药上的应用
CA2788526A1 (en) 2010-05-14 2011-11-17 Alembic Limited Extended release formulations of desvenlafaxine base
CN102249936B (zh) * 2010-05-19 2014-09-17 江苏豪森医药集团有限公司 O-去甲基文拉法辛盐酸盐的水合物及其制备方法
CN103588652B (zh) 2010-10-01 2015-04-22 山东绿叶制药有限公司 4-甲基苯甲酸4-[2-二甲基胺基-1-(1-羟基环己基)乙基]苯酯盐酸盐的多晶型物、制备方法及其应用
US8933123B2 (en) 2010-10-08 2015-01-13 Cadila Healthcare Limited Polymorphic forms of O-desmethyl-venlafaxine succinate
EP2685966A1 (de) 2011-03-17 2014-01-22 Lupin Limited Pharmazeutische retard-zusammensetzungen eines selektiven serotoninwiederaufnahmehemmers
BR112013025766A2 (pt) 2011-04-12 2016-12-20 Lupin Ltd composições farmacêuticas de liberação modificada de desvenlafaxina
US8481596B2 (en) 2011-06-08 2013-07-09 Lupin Limited Polymomorph of desvenlafaxine benzoate
UY35091A (es) * 2012-10-24 2014-05-30 Onyx Therapeutics Inc Formulaciones de liberacion modificada para oprozomib
CN104666291A (zh) * 2013-11-26 2015-06-03 山东绿叶制药有限公司 去甲基文拉法辛苯甲酸酯类化合物在制备改善性功能障碍药物中的应用
CN104352469A (zh) * 2014-11-20 2015-02-18 哈尔滨圣吉药业股份有限公司 一种琥珀酸去甲文拉法辛缓释片及其制备方法
CN106146323B (zh) * 2015-04-03 2021-05-25 石药集团中奇制药技术（石家庄）有限公司 一种琥珀酸去甲文拉法辛一水合物新晶型及制备方法
MX367362B (es) 2016-06-29 2019-08-16 Alparis Sa De Cv Nuevas formas solidas de desvenlafaxina.
EP3580198B1 (de) * 2017-02-09 2023-08-09 R L Finechem Private Limited Verfahren zur herstellung of1-[2-(dimethylamino)-1-(4-hydroxyphenyl) ethyl]-cyclohexanol und salzen davon
CN107082745A (zh) * 2017-04-21 2017-08-22 上海华源医药科技发展有限公司 一种改进的ⅰ型去甲文拉法辛琥珀酸盐的生产方法
US11400051B2 (en) * 2017-07-11 2022-08-02 Universal Stabilization Technologies, Inc. Method for preserving biopharmaceuticals
EP3661937B1 (de) 2017-08-01 2021-07-28 Gilead Sciences, Inc. Kristalline formen von ethyl ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl)-l-alaninat (gs-9131) zur behandlung von viralen infektionen
TWI805601B (zh) 2017-08-11 2023-06-21 南韓商愛茉莉太平洋股份有限公司 醫藥組成物及抑制其形成結晶的方法
KR102518632B1 (ko) 2018-04-18 2023-04-06 (주)아모레퍼시픽 (r)-n-[1-(3,5-다이플루오로-4-메테인설폰일아미노-페닐)-에틸]-3-(2-프로필-6-트라이플루오로메틸-피리딘-3-일)-아크릴아마이드를 함유하는 약학 조성물
TR201820634A2 (tr) 2018-12-27 2020-07-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Desvenlafaksi̇ni̇n kati oral farmasöti̇k kompozi̇syonlari

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) * 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4535186A (en) 1983-04-19 1985-08-13 American Home Products Corporation 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives
IE56324B1 (en) 1982-12-13 1991-06-19 American Home Prod Phenethylamine derivatives and intermediates therefor
US4761501A (en) * 1983-10-26 1988-08-02 American Home Products Corporation Substituted phenylacetamides
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) * 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
GB8902209D0 (en) 1989-02-01 1989-03-22 Wyeth John And Brother Limited Preparation of cyclohexanol derivatives and novel thioamide intermediates
IT1229203B (it) * 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) * 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) * 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
AU4542993A (en) 1992-06-23 1994-01-24 Sepracor, Inc. Methods and compositions for treating depression and other disorders using optically pure (+) sibutramine
AU4542893A (en) 1992-06-23 1994-01-24 Sepracor, Inc. Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine
US5591767A (en) * 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
ES2304041T3 (es) * 1993-06-28 2008-09-01 Wyeth Nuevos tratamientos que utilizan derivados de fenetilamina.
TW344661B (en) * 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
SG49680A1 (en) * 1994-02-14 1998-06-15 American Home Prod Medicament for the inducement of cognition enhancement
US5594586A (en) * 1994-05-02 1997-01-14 The United States Of America As Represented By The Secretary Of The Air Force Photorefractive limiting quadratic processor
IT1270594B (it) * 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5506270A (en) * 1995-01-30 1996-04-09 American Home Products Corporation Venlafaxine in the treatment of hypothalamic amenorrhea in non-depressed women
US5554383A (en) * 1995-04-06 1996-09-10 Trustees Of Tufts College Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression
US6274171B1 (en) 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
AU3075197A (en) † 1996-05-21 1997-12-09 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Novel methods of o-demethylation and n-deprotection
EP1036561A1 (de) † 1997-10-01 2000-09-20 Flemington Pharmaceutical Corporation Nichtpolare Spray zur bukkalen Anwendung
US6342533B1 (en) * 1998-12-01 2002-01-29 Sepracor, Inc. Derivatives of (−)-venlafaxine and methods of preparing and using the same
US6197828B1 (en) 1998-12-01 2001-03-06 Sepracor, Inc. Derivatives of (+)-venlafaxine and methods of preparing and using the same
PL350924A1 (en) * 1999-04-06 2003-02-10 Sepracor Inc Derivatives of venlafaxine and methods of preparing and using the same
KR100883477B1 (ko) † 1999-05-27 2009-02-16 아쿠스피어 인코포레이티드. 다공성 약물 매트릭스의 약제 조성물
US20020022662A1 (en) 1999-06-15 2002-02-21 American Home Products Corporation Enantiomers of O-desmethyl venlafaxine
AU5738700A (en) * 1999-06-15 2001-01-02 American Home Products Corporation Enantiomers of o-desmethyl venlafaxine
DE60221642T3 (de) * 2001-02-12 2017-10-26 Wyeth LLC (n.d.Ges.d. Staates Delaware) O-desmethyl-venlafaxine succinat salz
UA80543C2 (en) * 2001-12-04 2007-10-10 Wyeth Corp Method for the preparation of o-desmethylvenlafaxine
BR0311693A (pt) 2002-06-10 2005-03-22 Wyeth Corp Sal de formato de o-desmetil-venlafaxina
TWI306092B (en) 2003-03-11 2009-02-11 Wyeth Corp Process for preparation of phenethylamine derivatives
WO2005077340A1 (en) 2004-02-06 2005-08-25 Wyeth Multiparticulate o-desmethylvenlafaxine salts and uses thereof

Also Published As

Publication number Publication date
MXPA03007043A (es) 2003-11-18
CY1106952T1 (el) 2012-09-26
KR20030077614A (ko) 2003-10-01
HUP0303128A2 (hu) 2003-12-29
JP2004529877A (ja) 2004-09-30
PE20020877A1 (es) 2002-11-12
DE60221642D1 (en) 2007-09-20
WO2002064543A2 (en) 2002-08-22
CN1501909A (zh) 2004-06-02
EP1360169B2 (de) 2017-05-24
EA200300873A1 (ru) 2003-12-25
HN2002000030A (es) 2004-06-07
US20040044241A1 (en) 2004-03-04
ZA200307116B (en) 2005-02-23
PA8539901A1 (es) 2005-05-10
IL157340A (en) 2010-04-15
WO2002064543A3 (en) 2002-12-12
AU2002250058B2 (en) 2007-08-16
DE60221642T2 (de) 2008-05-21
EA011451B1 (ru) 2009-04-28
CA2436668C (en) 2009-05-26
PT1360169E (pt) 2007-10-29
NO328807B1 (no) 2010-05-18
US20030045583A1 (en) 2003-03-06
SI1360169T1 (sl) 2007-12-31
DK1360169T3 (da) 2007-11-26
DE60221642T3 (de) 2017-10-26
CA2666611A1 (en) 2002-08-22
KR100875610B1 (ko) 2008-12-26
PL364605A1 (en) 2004-12-13
EP1360169A2 (de) 2003-11-12
US20070037884A1 (en) 2007-02-15
CN101671260A (zh) 2010-03-17
IL200255A (en) 2010-12-30
CA2436668A1 (en) 2002-08-22
PL396568A1 (pl) 2012-02-13
NO20033538D0 (no) 2003-08-11
UY27175A1 (es) 2002-09-30
AR082076A2 (es) 2012-11-07
EP1360169B1 (de) 2007-08-08
IL209444A0 (en) 2011-07-31
US20050096479A1 (en) 2005-05-05
IL157340A0 (en) 2004-02-19
HUP0303128A3 (en) 2008-03-28
US7026508B2 (en) 2006-04-11
TWI318201B (en) 2009-12-11
ES2290281T3 (es) 2008-02-16
HK1057885A1 (en) 2004-04-23
JP4220243B2 (ja) 2009-02-04
US7291347B2 (en) 2007-11-06
EP2319826A1 (de) 2011-05-11
AR032671A1 (es) 2003-11-19
NZ539791A (en) 2006-11-30
EP1864967A1 (de) 2007-12-12
BR0207157A (pt) 2004-02-17
ES2290281T5 (es) 2017-09-11
IL209444A (en) 2012-10-31
NO20033538L (no) 2003-08-11
PL212943B1 (pl) 2012-12-31
PL211788B1 (pl) 2012-06-29
CN100567253C (zh) 2009-12-09
US6673838B2 (en) 2004-01-06
US20090018208A1 (en) 2009-01-15

Similar Documents

Publication Publication Date Title
ATE369330T1 (de) O-desmethyl-venlafaxine succinat salz
DE60227853D1 (de) Substituierte Pyridinylamine
IS7016A (is) Ný 4-anilínókínólín-3-karboxamíð
ATE319451T1 (de) Tetrahydrochinolin-derivate
NO20003968D0 (no) Farmasøytiske preparater
ATE312827T1 (de) 3-substituierte-4-pyrimidonderivate
NO20041689L (no) Substituerte tioacetamider
DE50206892D1 (de) Substituierte imidazotriazinone
ATE335486T1 (de) Hydrazono-malonitrile
DE60221403D1 (de) Doppelstrom - verdichter
EE200300447A (et) Asendatud bensofuraan-2-karboksamiidide derivaadid
NO20014597D0 (no) Fremgangsmåte
IS2523B (is) Turn vindorkuvers
DK1373228T3 (da) Substituerede fluoralkoxyphenylsulfonylurinstoffer
DK1331972T3 (da) Farmaceutiske præparater
DE60223031D1 (de) Arylpiperazin gebundene tetrahydroindolonderivate
ATE435197T1 (de) Substituierte 4-aminocyclohexanole
ATE382601T1 (de) Substituierte 4-aminocyclohexanolderivate
ATA18372001A (de) Gelenksbolzenbaueinheit
ATE319694T1 (de) Phenylalkyne
DE60202381D1 (de) Paroxetin-n-formyl-derivate
ATA13992002A (de) Schlackengranulierungsanlage
DE60216967D1 (de) Substituierte cyclohexanderivate
ATE345337T1 (de) Delta1 -pyrroline
AT500276B8 (de) Radschwenksystem

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1360169

Country of ref document: EP